Portage Biotech Inc
NASDAQ:PRTG

Watchlist Manager
Portage Biotech Inc Logo
Portage Biotech Inc
NASDAQ:PRTG
Watchlist
Price: 4.7001 USD -0.84% Market Closed
Market Cap: $10.7m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
CA
Portage Biotech Inc
NASDAQ:PRTG
10.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Portage Biotech Inc
Glance View

Market Cap
10.7m USD
Industry
Biotechnology

Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2013-10-28. The firm is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Its portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

PRTG Intrinsic Value
1.0412 USD
Overvaluation 78%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top